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Background: Attention-deﬁcit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that af-
fects the lives of patients and their families. The Caregiver Perspective on Paediatric ADHD (CAPPA)
survey was conducted to evaluate the burden associated with ADHD in Europe and to identify unmet
needs. Here, we describe sociodemographic and clinical characteristics, treatment use and impact of
ADHD.
Methods: The cross-sectional web-based CAPPA survey was ﬁelded in 10 European countries among
caregivers of children/adolescents (aged 6–17 years) with ADHD who were currently receiving or had
received pharmacotherapy in the previous 6 months.
Results: Data on 3688 completed CAPPA surveys were evaluated. Children/adolescents were diagnosed
with ADHD at a mean age of 6.9 years; 80% were male. Most children/adolescents (56%) had undergone
behavioural therapy. Overall, 78% of children/adolescents currently received ADHD pharmacotherapy; high
rates of atypical antipsychotic use were reported in some countries. Overall, 23% of children/adolescents
had repeated a school year and 4% had been expelled recently. Most caregivers (68–88%) reported difﬁculty
with schoolwork, social interactions/activities and family relationships, even when the child/adolescent
was receiving ADHD medication. Almost one third (31%) of caregivers felt the need to change employment
status despite their child/adolescent receiving ADHD medication in 53% of these cases.
Limitations: Information was reported by caregivers recruited through market research panels; reporting,
recall and selection biases may be present.
Conclusion: Variation across Europe was observed in characteristics of caregivers and children/adolescents
with ADHD, and treatment use. Even with medication, ADHD compromised or negatively impacted
caregivers’ work and children/adolescents’ schoolwork, their social interactions and family relationships.
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od).1. Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) affects 3–5% of
children and adolescents worldwide (Polanczyk et al., 2007, 2014,
2015). This neurodevelopmental disorder is characterized by core
features of hyperactivity, impulsivity and inattention (American
Psychiatric Association, 2013; NICE, 2013). Functional impairment
must also be present to meet ADHD diagnostic criteria (American
E. Flood et al. / Journal of Affective Disorders 200 (2016) 222–234 223Psychiatric Association, 2013; NICE, 2013; World Health Organi-
zation, 2010). Psychological, social, educational and/or occupa-
tional impairment can have long-term consequences for an in-
dividual's health-related quality of life (Danckaerts et al., 2010;
Klassen et al., 2004; Riley et al., 2006a). ADHD can also adversely
affect the daily lives of parents or caregivers and other family
members by causing difﬁculties at home and strain on relation-
ships (Escobar et al., 2005; Harpin, 2005). The inﬂuence of hy-
peractivity and impulsivity on academic and social functioning
also adds to the burden of families of children/adolescents with
ADHD (Chen et al., 2014).
ADHD diagnostic and management practices vary by geo-
graphic location (Hinshaw et al., 2011; Seixas et al., 2012; Setya-
wan et al., 2015). Medical and behavioural therapy (BT) help re-
duce ADHD symptoms (MTA Cooperative Group, 1999) but the
availability of, and access to, different treatment modalities varies
across countries (Hinshaw et al., 2011; Hodgkins et al., 2013;
Seixas et al., 2012; Setyawan et al., 2015). In general, European
guidelines recommend multidisciplinary management that in-
volves pharmacological treatment plus educational, psychological
and behavioural interventions (Deutsche Gesellschaft für Kinder-
und Jugendpsychiatrie und Psychotherapie, 2007; Health Ministry
of Spain, 2010; Landelijke Stuurgroep, 2007; NICE, 2013; SINPIA,
2002; Taylor et al., 2004). Pharmacotherapies currently approved
for use in Europe include short- and long-acting formulations of
stimulants such as methylphenidate and amphetamines, and the
non-stimulants atomoxetine and guanfacine extended-release.
European guidelines suggest the use of methylphenidate for initial
pharmacological treatment of ADHD (Banaschewski et al., 2006;
Taylor et al., 2004), and national guidelines in the UK, Spain,
Germany, the Netherlands and Italy are generally consistent with
this approach (Deutsche Gesellschaft für Kinder- und Jugen-
dpsychiatrie und Psychotherapie, 2007; Health Ministry of Spain,
2010; Landelijke Stuurgroep, 2007; NICE, 2013; SINPIA, 2002).
Although pharmacological and non-pharmacological interventions
may help reduce ADHD symptoms, some individuals continue to
experience symptoms or functional impairment that negatively
affect their own/their family's lives (Preuss et al., 2006; Ralston
and Lorenzo, 2004). For example, approximately 30% of children/
adolescents with ADHD fail to respond to treatment with a single
stimulant and 10% do not respond to any stimulants (Arnold,
2000; Spencer et al., 1996).
‘Real-world’ studies can be used to identify and evaluate a
broad range of issues that concern patients with ADHD and their
families. Furthermore, real-world information on treatment use
from patients or caregivers includes a broader and more hetero-
geneous population than those who are enrolled in clinical trials
and may better reﬂect actual practice. The web-based cross-sec-
tional Caregiver Perspective on Paediatric ADHD (CAPPA) survey
was designed to evaluate the burden associated with ADHD and its
treatment, and identify unmet needs in the management of this
condition. To our knowledge, this is the ﬁrst and largest commu-
nity-based study to report on the burden and unmet needs of
ADHD across many European countries. Sociodemographic and
clinical characteristics, and treatment use, are described for the
survey sample. We also present data on the impact of ADHD on the
caregiver's social and family interactions and work, and on their
child/adolescent's social interactions and schoolwork.2. Methods
2.1. Study design
This cross-sectional survey of caregivers of children/adolescents
aged 6–17 years with ADHD was conducted online betweenNovember 2012 and April 2013 in Denmark, Finland, France, Ger-
many, Italy, the Netherlands, Norway, Spain, Sweden and the UK.
2.2. Survey development
The survey was developed using concept elicitation methods
that involved collection and analysis of qualitative data from 38
caregivers and 28 adolescents on areas of unmet need affecting
children/adolescents with ADHD and their caregivers (Sikirica
et al., 2015). Key domains identiﬁed were: difﬁculty obtaining a
diagnosis; treatment effectiveness, satisfaction and compliance;
impact of ADHD on the child (academic, family, social); impact of
the child's ADHD on the caregiver (time, emotions, family, social,
work); perceived support from school and healthcare systems; and
perceived quality of care (Sikirica et al., 2015).
2.3. Survey questionnaire
The survey included questions on sociodemographic char-
acteristics of caregivers and their child/adolescent with ADHD.
From a predeﬁned list based on those previously identiﬁed as
common in an ADHD claims database study (Sikirica et al., 2013a),
caregivers were asked to select any comorbid conditions/beha-
viours for which their child/adolescent has a current physician
diagnosis. Caregivers were also required to record which medica-
tion(s) their child/adolescent received for ADHD using a pre-spe-
ciﬁed list identiﬁed using various treatment guidelines and clinical
input, or a free-text ﬁeld (i.e. ‘Other, please specify’).
Caregivers were asked to report on the child/adolescent's
ADHD when ‘on medication’ and ‘off medication’. Time off medi-
cation was deﬁned as the following: the child/adolescent forgot to
take medication; the child/adolescent intentionally chose not to
take medication (e.g. holidays or weekends); in the afternoon or
evening when the medication had worn off; or in the morning
prior to the medication taking effect. These questions were in-
cluded to evaluate the inﬂuence of ADHD treatment on the child/
adolescent (in terms of symptoms [using the ADHD-Rating Scale-
IV] and academic, family and social functioning), and the impact of
the child/adolescent's ADHD on their caregiver (in terms of time,
emotions, family, social and work). Only caregivers who reported
that their child/adolescent had been off medication for any time in
the past 6 months answered the off medication questions.
2.4. Survey translation
A cognitive debrieﬁng study was conducted among UK care-
givers (n¼52) to conﬁrm their ability to understand and complete
the survey, and the appropriateness/comprehensiveness of survey
items and response options. The survey was translated into local
languages using single forward and backward translation metho-
dology, and linguistically and culturally validated through cogni-
tive interviews with ﬁve caregivers from each non-English-
speaking country.
2.5. Ethical review
The study was reviewed and approved by a central institutional
review board (IRB), MaGil IRB, and was performed in accordance
with ethical standards of the Declaration of Helsinki. Caregivers
were asked to provide informed consent before completing the
survey.
2.6. Participants
Potential participants were identiﬁed by two market research
companies using patient panels comprising individuals who had
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market research companies recruited patients from proprietary
market research panels and those owned or maintained by various
professional providers. Members were recruited to the market
research panels using multiple approaches, including social media,
online communities and website advertising.
An electronic screening questionnaire accessed via a URL was
used to identify eligible participants. Caregivers were eligible to
participate in the CAPPA survey if they reported that they were
aged 18 years or older and a parent or legal guardian of at least one
child aged 6–17 years with a diagnosis of attention-deﬁcit disorder
(ADD)/ADHD made by a physician at least 6 months prior to
screening. The child/adolescent must have lived with the caregiver
for at least 50% of the time in the 6 months prior to the survey. In
addition, the child/adolescent had to be receiving, or have received
within 6 months prior to the survey, pharmacotherapy for ADD/
ADHD.
Caregivers were excluded if they reported having one or more
of the following conditions: dementia, schizophrenia, schi-
zoaffective disorder, schizophreniform disorder, brief psychotic
disorder, delusional disorder, shared psychotic disorder, sub-
stance-induced psychotic disorder, psychotic disorder due to
medical condition, or paraphrenia. Caregivers were also excluded
if they reported consuming more than ﬁve alcoholic drinks per
day, or if they reported that their child had signiﬁcant cognitive
impairment (IQo70).
After completing the screening questionnaire, eligible care-
givers were directed to the survey itself. For caregivers with more
than one child who met the study criteria, the screener was pro-
grammed to randomly select one of the eligible children as the
subject for the survey. Use of speciﬁc software technology re-
stricted completion of surveys to one per computer.
2.7. Analyses
To protect participant conﬁdentiality, no identifying information
was collected or received by the study team. A data cleaning pro-
cedure was utilized such that caregivers with Z3 inconsistent (il-
logical) responses were excluded from analyses; caregivers with in-
valid responses to free-text questions (e.g. ‘Other, please specify’)
were also evaluated for exclusion prior to any data analysis.
Sociodemographic characteristics of caregivers, socio-
demographic and clinical characteristics of children/adolescents
with ADHD, and treatment use data are presented here for the
overall sample and by individual country; data on the impact of
ADHD on work are presented for the overall sample, and data on
school, the family and social activities are presented only for those
patients with both on- and off-medication data. Data from Den-
mark, Finland and Norway were combined for analysis because of
the small sample sizes available for individual countries and are
hereafter termed ‘Nordic countries’; data from Sweden are pre-
sented separately.
Disease burden and unmet needs may vary with medication
use. Therefore, we assessed the inﬂuence of ADHD medication on
disease burden and unmet needs using two mutually exclusive
subgroups: children/adolescents who were receiving ADHD med-
ication when the survey was conducted (designated ‘current
medication use’) and those who had discontinued ADHD medi-
cation within the previous 6 months and were not receiving
pharmacotherapy when the survey was conducted (designated
‘recent medication use’).
Descriptive analyses (number, percentage; median, range;
mean, standard deviation [SD]) are reported for most outcomes.
The Wilcoxon Signed Rank test was used to compare the dis-
tribution of responses on versus off medication; no formal statis-
tical comparisons were made between countries.3. Results
3.1. Participants
A total of 205,187 potential participants clicked on the URL to
take the eligibility screening test; all participants were recruited
through market research panels. Of these, 1.4% (n¼2870) did not
complete the screening process and 94.9% (n¼194,706) failed to
meet the required criteria. A total of 7611 (3.7%) participants
passed the screening test and of these 50.8% (n¼3868) completed
the survey. Surveys from 180 (4.7%) participants with a high fre-
quency of illogical or inconsistent responses were excluded. Sub-
ject disposition is presented in Supplementary Fig. S1. Thus, data
on 3688 completed CAPPA surveys were evaluated. Percentages
(numbers) of evaluable surveys by country are presented in
Table 1a. The average length of time for survey completion was
31 min.
3.2. Sociodemographic characteristics of caregivers
The sociodemographic characteristics of the caregivers who
participated in the survey are presented for the overall sample and
by country (Table 1a). The majority of caregivers were female (66%
overall) and most were married (81%). Approximately half (51%)
were employed full-time and 21% were employed part-time. Em-
ployment status varied widely among countries; Italy had the
highest proportion (71%) of caregivers employed full-time and the
Netherlands the lowest (26%). Sweden and Spain had the highest
unemployment rates (12% and 11%, respectively), and the UK the
lowest (3%).
A small proportion (8%) of parents reported having ADHD
themselves; this was highest in the ‘Nordic countries’ (16%) and
lowest in the UK (3%). In total, 27% of caregivers reported that at
least one other household member had ADHD. This varied among
countries, with the Netherlands and Sweden having the highest
proportion (46% and 44%, respectively), and the UK, Italy and Spain
having the lowest proportion (19%, 21% and 21%, respectively).
Overall, 27% of caregivers reported receiving no training or
education on ADHD for themselves or their children. For those
who had received training/education, the most common form was
written/verbal education (47%), followed by family therapy with
the child (24%). Social and occupational therapies were the least
common (12% for each).
Sociodemographic characteristics of children/adolescents with ADHD
Sociodemographic characteristics of the children/adolescents
represented in the survey are given for the overall sample and by
country (Table 1b). The majority (80%) of children/adolescents
were male, ranging from 70% (Sweden) to 84% (France). Ages
ranged from 6 to 17 years. Median age overall was 12 years, and
ranged from 10 (France, Italy) to 13 (the Netherlands, Sweden)
years.
Overall, 82% of the children/adolescents in the sample were
currently attending a mainstream school. The Netherlands, ‘Nordic
countries’ and France had the highest rates of children attending
special needs schools (27%, 27% and 21%, respectively); Spain and
Italy had the lowest rates (5% and 8%, respectively). According to
the caregiver, poor or failing school marks had been received by
21% of children/adolescents in the overall sample; variation among
countries was seen, ranging from 7% (Italy) to 41% (Sweden).
Nearly a quarter of the overall sample (23%) had repeated a school
year because of their ADHD; this was seen most frequently (30–
40%) in the Netherlands, Spain and France. Overall, 4% of the
sample had been expelled from school in the past 6 months, most
frequently in France, the UK and Spain.
Table 1
Sociodemographic characteristics of (a) caregivers and (b) children/adolescents with ADHD as reported by caregivers.
a) Pan-EU
(N¼3688,
100%)
France
(n¼486,
13.2%)
Germany
(n¼589,
16.0%)
Italy
(n¼468,
12.7%)
Netherlands
(n¼316, 8.6%)
Nordics
(n¼249,
6.8%a)
Sweden
(n¼219,
5.9%)
Spain
(n¼574,
15.6%)
UK
(n¼787,
21.3%)
Females 2422 (65.7) 319 (65.6) 392 (66.6) 309 (66.0) 233 (73.7) 142 (57.0) 136 (62.1) 344 (59.9) 547 (69.5)
Caregiver's relationship to child
Mother 2351 (63.7) 310 (63.8) 377 (64.0) 305 (65.2) 227 (71.8) 136 (54.6) 135 (61.6) 339 (59.1) 522 (66.3)
Father 1097 (29.7) 154 (31.7) 160 (27.2) 144 (30.8) 72 (22.8) 92 (36.9) 70 (32.0) 210 (36.6) 195 (24.8)
Other (relative/
guardian)
240 (6.5) 22 (4.5) 52 (8.8) 19 (4.1) 17 (5.4) 21 (8.4) 14 (6.4) 25 (4.3) 70 (8.9)
Prevalence of ADHD in family
Mother 308 (8.4) 53 (10.9) 49 (8.3) 47 (10.0) 33 (10.4) 37 (14.9) 24 (11.0) 33 (5.7) 32 (4.1)
Father 235 (6.4) 25 (5.1) 38 (6.5) 24 (5.1) 33 (10.4) 27 (10.8) 27 (12.3) 27 (4.7) 34 (4.3)
Brother(s) 302 (8.2) 23 (4.7) 70 (11.9) 18 (3.8) 51 (16.1) 24 (9.6) 23 (10.5) 34 (5.9) 59 (7.5)
Sister(s) 171 (4.6) 8 (1.6) 39 (6.6) 10 (2.1) 22 (7.0) 19 (7.6) 27 (12.3) 17 (3.0) 29 (3.7)
None 2708 (73.4) 377 (77.6) 410 (69.6) 373 (79.7) 174 (55.1) 157 (63.1) 124 (56.6) 457 (79.6) 636 (80.8)
Self-reported ADHD diagnosis
Mothers 221 (9.4) 39 (12.6) 39 (10.3) 35 (11.5) 28 (12.3) 26 (19.1) 16 (11.9) 19 (5.6) 19 (3.6)
Fathers 59 (5.4) 11 (7.1) 9 (5.6) 7 (4.9) 5 (6.9) 10 (10.9) 7 (10.0) 4 (1.9) 6 (3.1)
Marital status
Married 2988 (81.0) 410 (84.4) 470 (79.8) 439 (93.8) 243 (76.9) 179 (71.9) 160 (73.1) 494 (86.1) 593 (75.3)
Single 342 (9.3) 38 (7.8) 44 (7.5) 18 (3.8) 32 (10.1) 33 (13.3) 39 (17.8) 24 (4.2) 114 (14.5)
Divorced 334 (9.1) 32 (6.6) 68 (11.5) 9 (1.9) 41 (13.0) 36 (14.5) 19 (8.7) 52 (9.1) 77 (9.8)
Widowed 24 (0.7) 6 (1.2) 7 (1.2) 2 (0.4) 0 (0.0) 1 (0.4) 1 (0.5) 4 (0.7) 3 (0.4)
Employment status
Employed, full-time 1886 (51.1) 292 (60.1) 271 (46.0) 334 (71.4) 82 (25.9) 144 (57.8) 113 (51.6) 326 (56.8) 324 (41.2)
Employed, part-
time
788 (21.4) 80 (16.5) 161 (27.3) 55 (11.8) 130 (41.1) 38 (15.3) 52 (23.7) 90 (15.7) 182 (23.1)
Homemaker 521 (14.1) 64 (13.2) 86 (14.6) 54 (11.5) 49 (15.5) 12 (4.8) 4 (1.8) 61 (10.6) 191 (24.3)
Retired/disabled 135 (3.7) 8 (1.6) 24 (4.1) 2 (0.4) 16 (5.1) 18 (7.2) 12 (5.5) 18 (3.1) 37 (4.7)
Other/student/self-
employed
124 (3.4) 14 (2.9) 26 (4.4) 5 (1.1) 9 (2.8) 17 (6.8) 11 (5.0) 13 (2.3) 29 (3.7)
Unemployed 234 (6.3) 28 (5.8) 21 (3.6) 18 (3.8) 30 (9.5) 20 (8.0) 27 (12.3) 66 (11.5) 24 (3.0)
Highest level of education
No formal
qualiﬁcations
119 (3.2) 11 (2.3) 27 (4.6) 7 (1.5) 11 (3.5) 10 (4.0) 0 (0.0) 12 (2.1) 41 (5.2)
GCSE/O-level or
equivalent
911 (24.7) 58 (11.9) 320 (54.3) 21 (4.5) 42 (13.3) 59 (23.7) 20 (9.1) 132 (23.0) 259 (32.9)
A-level or
equivalent
1204 (32.6) 140 (28.8) 133 (22.6) 149 (31.8) 158 (50.0) 89 (35.7) 137 (62.6) 172 (30.0) 226 (28.7)
University or higher 1454 (39.4) 277 (57.0) 109 (18.5) 291 (62.1) 105 (33.2) 91 (36.5) 62 (28.3) 258 (44.9) 261 (33.2)
Children per household
Mean (SD) 2.05 (1.01) 2.07 (0.91) 1.95 (0.97) 1.74 (1.00) 2.37 (0.99) 2.12 (1.05) 2.19 (1.14) 1.88 (0.83) 2.22 (1.11)
Range 1–10 1–6 1–8 1–10 1–10 1–9 1–7 1–9 1–8
ADHD education/trainingb
None received 1012 (27.4) 174 (35.8) 151 (25.6) 118 (25.2) 86 (27.2) 47 (18.9) 45 (20.5) 152 (26.5) 239 (30.4)
Written and verbal
information
1729 (46.9) 159 (32.7) 274 (46.5) 227 (48.5) 138 (43.7) 150 (60.2) 140 (63.9) 307 (53.5) 334 (42.4)
Group sessions (for
caregivers)
759 (20.6) 66 (13.6) 126 (21.4) 92 (19.7) 72 (22.8) 69 (27.7) 70 (32.0) 113 (19.7) 151 (19.2)
Individual sessions
(for caregivers)
533 (14.5) 65 (13.4) 107 (18.2) 88 (18.8) 58 (18.4) 42 (16.9) 34 (15.5) 51 (8.9) 88 (11.2)
Family therapy with
child
874 (23.7) 123 (25.3) 141 (23.9) 129 (27.6) 77 (24.4) 64 (25.7) 35 (16.0) 128 (22.3) 177 (22.5)
Family therapy
without child
493 (13.4) 59 (12.1) 81 (13.8) 75 (16.0) 48 (15.2) 49 (19.7) 26 (11.9) 83 (14.5) 72 (9.1)
Social therapy for
child
426 (11.6) 30 (6.2) 113 (19.2) 59 (12.6) 65 (20.6) 21 (8.4) 7 (3.2) 64 (11.1) 67 (8.5)
Occupational ther-
apy for child
428 (11.6) 35 (7.2) 118 (20.0) 26 (5.6) 53 (16.8) 35 (14.1) 25 (11.4) 49 (8.5) 87 (11.1)
Other (including
self-taught)
120 (3.3) 24 (4.9) 40 (6.8) 1 (0.2) 15 (4.7) 6 (2.4) 12 (5.5) 23 (4.0) 12 (1.5)
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Table 1 (continued )
b) Pan-EU
(N¼3688)
France
(n¼486)
Germany
(n¼589)
Italy
(n¼468)
Netherlands
(n¼316)
Nordics
(n¼249)
Sweden
(n¼219)
Spain
(n¼574)
UK(n¼787)
Males 2932 (79.5) 408 (84.0) 459 (77.9) 367 (78.4) 235 (74.4) 201 (80.7) 154 (70.3) 451 (78.6) 657 (83.5)
Median age (range),
years
12 (6–17) 10 (6–17) 12 (6–17) 10 (6–17) 13 (6–17) 12 (6–17) 13 (6–17) 12 (6–17) 12 (6–17)
School type
Mainstream 3041 (82.5) 374 (77.0) 500 (84.9) 423 (90.4) 219 (69.3) 177 (71.1) 178 (81.3) 542 (94.4) 628 (79.8)
Special needs
speciﬁc
559 (15.2) 100 (20.6) 84 (14.3) 37 (7.9) 85 (26.9) 66 (26.5) 34 (15.5) 26 (4.5) 127 (16.1)
Home-schooled 44 (1.2) 11 (2.3) 2 (0.3) 6 (1.3) 1 (0.3) 4 (1.6) 5 (2.3) 5 (0.9) 10 (1.2)
Otherc 44 (1.2) 1 (0.2) 3 (0.5) 2 (0.4) 11 (3.5) 2 (0.8) 2 (0.9) 1 (0.2) 22 (2.8)
Most recent school marks
Excellent/good 1219 (33.1) 183 (37.7) 180 (30.6) 157 (33.5) 120 (38.0) 71 (28.5) 40 (18.3) 165 (28.7) 303 (38.5)
Fair 1698 (46.0) 191 (39.3) 319 (54.2) 278 (59.4) 158 (50.0) 120 (48.2) 89 (40.6) 260 (45.3) 283 (36.0)
Poor/failing 771 (20.9) 112 (23.0) 90 (15.3) 33 (7.1) 38 (12.0) 58 (23.3) 90 (41.1) 149 (26.0) 201 (25.5)
Repeated a year in
school (ever)
853 (23.1) 148 (30.5) 160 (27.2) 45 (9.6) 127 (40.2) 44 (17.7) 46 (21.0) 206 (35.9) 77 (9.8)
School expulsion
(in last 6 months)
146 (4.0) 29 (6.0) 19 (3.2) 11 (2.4) 7 (2.2) 5 (2.0) 5 (2.3) 28 (4.9) 42 (5.3)
All numbers are reported as n (%) unless stated otherwise.
ADHD, attention-deﬁcit/hyperactivity disorder; SD, standard deviation.
a Denmark, 3.0%; Finland, 2.8%; Norway, 1.0%.
b Refers to education/training for both caregiver and child.
c Includes ‘not in school’ and ‘attending vocational school’.
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Age at diagnosis: Caregivers reported that their child/adoles-
cent had been formally diagnosed with ADHD at a mean (SD) age
of 6.9 (3.0) years (Table 2); this ranged from 6.3 (2.8) years in
France to 8.3 (3.6) years in Sweden.
Duration since ADHD diagnosis: Overall, caregivers reported
that their child/adolescent had been formally diagnosed with
ADHD a mean (SD) of 4.6 (3.2) years prior to the survey; this
ranged from 3.4 (2.4) years in Italy to 5.4 (3.1) years in Germany
(Table 2). Children/adolescents who were currently receiving
ADHD medication had a shorter duration since ADHD diagnosis
than did those who had previously received medication (4.3 vs
4.9 years).
ADHD severity: About half (52%) of caregivers described their
child/adolescent's ADHD as moderate in severity, with 24% de-
scribing it as very mild/mild and 25% as severe/very severe at the
time of the survey (Table 2). Italy had the lowest proportion (12%)
of caregivers describing their child/adolescent's ADHD as severe/
very severe, and the highest proportion (37%) describing their
child/adolescent as having very mild/mild ADHD. Germany (33%),
the Netherlands (33%) and the UK (31%) had the highest propor-
tions of caregivers describing their child/adolescent as having se-
vere/very severe ADHD.
Comorbidities: Almost half of children/adolescents (49%) were
reported by caregivers to have at least one comorbid condition or
behaviour (Table 2); this varied from 36% (Spain) to 57% (Italy).
Anxiety, learning difﬁculties, conduct disorder and aggression
were the most commonly reported comorbid conditions/beha-
viours; each was present in 410% of the overall sample. Almost a
quarter of Italian (23%) and French (22%) caregivers reported that
their child/adolescent experienced anxiety. Germany had the
highest percentage of children/adolescents reported to have
learning difﬁculties (19%). French caregivers reported the highest
number of children/adolescents with conduct disorder (24%).
UK caregivers reported the lowest prevalence of conductdisorder (3%). Aggression was most frequently reported in Italy
(17%), followed by the UK (15%).
Of other commonly reported comorbid conditions, 19% of
caregivers in the Netherlands reported that their child/adolescent
had autism compared with only 7% in the total pan-European
sample. Caregivers in Sweden reported the highest percentage of
children/adolescents with Asperger's syndrome (13%), followed by
the UK (12%). The highest percentage of children/adolescents with
comorbid depression (11%) was also reported for Sweden.
3.4. ADHD treatment use
Behavioural therapy: Caregivers reported that the majority
(56%) of children/adolescents had received BT (or cognitive BT) for
ADHD (Table 3). BT was least commonly reported in Sweden (23%)
and most commonly reported in Germany (63%), Spain (65%) and
Italy (77%). More than half (53%) of children/adolescents in Italy
were still receiving BT at the time of survey completion.
Overall, 36% of children/adolescents received BT prior to
pharmacotherapy. The rate was highest in Italy, where 61% of all
children/adolescents received BT before starting medication. More
than half (57%) of those who received BT prior to pharmacother-
apy were reported to have done so for o6 months before starting
medication. One third (33%) of Swedish children/adolescents did
not continue 41 month, and none of the Swedish children/
adolescents persisted with BT for 412 months, prior to starting
medication.
The most common reason for stopping BT selected by care-
givers in the overall sample was that it did not help to improve (at
least one of) hyperactivity, impulsivity, concentration or behaviour
(44%). The second most common reason was that it was no longer
needed with the aid of medication (30%); more than a third of
caregivers in Spain (39%), Italy (36%), the Netherlands (35%) and
‘Nordic countries’ (34%) selected this reason.
Pharmacotherapy: Current or most recent medications received
by children/adolescents are summarized in Table 4. Stimulants
Table 2
Clinical characteristics of children/adolescents with ADHD as reported by caregivers.
Pan-EU
(N¼3688)
France
(n¼486)
Germany
(n¼589)
Italy
(n¼468)
Netherlands
(n¼316)
Nordicsa
(n¼249)
Sweden
(n¼219)
Spain
(n¼574)
UK
(n¼787)
Age at formal diagnosis, years
Mean (SD) 6.90 (3.02) 6.32 (2.79) 6.51 (2.61) 6.63 (3.18) 7.31 (3.18) 7.41 (3.17) 8.28 (3.58) 6.74 (3.02) 7.09 (2.91)
Range 0–17 0–16 0–16 0–15 0–16 0–16 0–16 0–15 0–17
Time since formal diagnosis, years
Mean (SD) 4.58 (3.17) 4.33 (3.01) 5.40 (3.12) 3.40 (2.36) 5.09 (3.28) 4.64 (3.03) 4.14 (3.08) 4.82 (3.15) 4.55 (3.49)
Range 0–17 1–17 1–15 1–14 1–15 1–13 1–16 1–16 0–15
Reported current severity of ADD/ADHDb
Very mild/mild 879 (23.8) 124 (25.5) 102 (17.3) 175 (37.4) 46 (14.6) 54 (21.7) 47 (21.5) 168 (29.3) 163 (20.7)
Moderate 1901 (51.5) 250 (51.4) 291 (49.4) 236 (50.4) 167 (52.8) 137 (55.0) 112 (51.1) 324 (56.4) 384 (48.8)
Severe/very severe 908 (24.6) 112 (23.0) 196 (33.3) 57 (12.2) 103 (32.6) 58 (23.3) 60 (27.4) 82 (14.3) 240 (30.5)
Reported comorbid conditions or behaviours
None 1864 (50.5) 233 (47.9) 306 (52.0) 203 (43.4) 162 (51.3) 124 (49.8) 101 (46.1) 369 (64.3) 366 (46.5)
Aggression 395 (10.7) 66 (13.6) 62 (10.5) 80 (17.1) 16 (5.1) 15 (6.0) 19 (8.7) 18 (3.1) 119 (15.1)
Alcohol abuse 29 (0.8) 6 (1.2) 7 (1.2) 2 (0.4) 2 (0.6) 2 (0.8) 2 (0.9) 3 (0.5) 5 (0.6)
Anxiety 489 (13.3) 105 (21.6) 45 (7.6) 108 (23.1) 38 (12.0) 19 (7.6) 21 (9.6) 52 (9.1) 101 (12.8)
Asperger's syndrome 203 (5.5) 9 (1.9) 16 (2.7) 7 (1.5) 13 (4.1) 15 (6.0) 29 (13.2) 19 (3.3) 95 (12.1)
Autism 263 (7.1) 4 (0.8) 9 (1.5) 10 (2.1) 60 (19.0) 24 (9.6) 28 (12.8) 12 (2.1) 116 (14.7)
Bipolar disorder 61 (1.7) 17 (3.5) 7 (1.2) 20 (4.3) 1 (0.3) 2 (0.8) 5 (2.3) 5 (0.9) 4 (0.5)
Cerebral palsy 8 (0.2) 1 (0.2) 4 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.2) 1 (0.1)
Conduct disorder 434 (11.8) 116 (23.9) 97 (16.5) 61 (13.0) 38 (12.0) 34 (13.7) 9 (4.1) 58 (10.1) 21 (2.7)
Depression 197 (5.3) 18 (3.7) 34 (5.8) 24 (5.1) 12 (3.8) 16 (6.4) 25 (11.4) 19 (3.3) 49 (6.2)
Drug abuse 31 (0.8) 1 (0.2) 8 (1.4) 3 (0.6) 3 (0.9) 1 (0.4) 3 (1.4) 8 (1.4) 4 (0.5)
Eating disorder 137 (3.7) 28 (5.8) 32 (5.4) 17 (3.6) 6 (1.9) 6 (2.4) 7 (3.2) 19 (3.3) 22 (2.8)
Epilepsy 46 (1.2) 11 (2.3) 2 (0.3) 6 (1.3) 1 (0.3) 6 (2.4) 2 (0.9) 10 (1.7) 8 (1.0)
Learning difﬁculties 462 (12.5) 74 (15.2) 111 (18.8) 53 (11.3) 31 (9.8) 30 (12.0) 28 (12.8) 46 (8.0) 89 (11.3)
Motor-coordination
disorder
140 (3.8) 28 (5.8) 34 (5.8) 12 (2.6) 11 (3.5) 12 (4.8) 3 (1.4) 12 (2.1) 28 (3.6)
Obsessive compulsive
disorder
116 (3.1) 14 (2.9) 10 (1.7) 11 (2.4) 5 (1.6) 8 (3.2) 10 (4.6) 18 (3.1) 40 (5.1)
Oppositional deﬁant
disorder
163 (4.4) 26 (5.3) 25 (4.2) 14 (3.0) 14 (4.4) 10 (4.0) 8 (3.7) 23 (4.0) 43 (5.5)
Schizoaffective disorder 9 (0.2) 1 (0.2) 2 (0.3) 4 (0.9) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.2) 0 (0.0)
Schizophrenia 11 (0.3) 1 (0.2) 2 (0.3) 6 (1.3) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.1)
Sleep disorder 305 (8.3) 55 (11.3) 43 (7.3) 30 (6.4) 29 (9.2) 17 (6.8) 24 (11.0) 24 (4.2) 83 (10.5)
Speech/language
disorder
183 (5.0) 23 (4.7) 30 (5.1) 28 (6.0) 4 (1.3) 15 (6.0) 12 (5.5) 26 (4.5) 45 (5.7)
Tourette’s syndrome 56 (1.5) 4 (0.8) 9 (1.5) 2 (0.4) 2 (0.6) 10 (4.0) 3 (1.4) 3 (0.5) 23 (2.9)
All numbers are reported as n (%) unless stated otherwise.
ADD, attention-deﬁcit disorder; ADHD, attention-deﬁcit/hyperactivity disorder.
a Denmark, Finland and Norway.
b As described by the caregiver.
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mine/dexamphetamine; non-stimulants included atomoxetine or
guanfacine; atypical antipsychotics (AAPs; not licensed for the
treatment of ADHD) included aripiprazole, risperidone, quetiapine
and olanzapine.
The majority (78%) of children/adolescents included in the
survey were currently prescribed pharmacotherapy for ADHD. Of
these, most (83%) were currently receiving stimulant therapy.
Across countries, the use of stimulant therapy was most prevalent
in Germany and the Netherlands (93% each) and least prevalent in
Italy (60%). Non-stimulant therapy was most common among
current medication users in Sweden (18%) and France (15%). The
most common combination of therapies currently being received
was stimulant medication and an AAP (5%); this combination was
most prevalent in Italy (10%) and France (8%).
Overall, 6.4% of children/adolescents were reported to be cur-
rently receiving AAPs as a component of combination therapy. Afurther 10% were currently receiving AAP monotherapy. AAP
monotherapy use varied among countries; the highest rates of
current AAP monotherapy use were reported in Italy (34%), France
(11%) and Spain (11%; Table 4). Use of AAPs for the treatment of
ADHD would represent off-label prescribing; however, AAPs are
sometimes used to treat comorbidities. Therefore, we further
evaluated comorbid conditions/behaviours that were reported
among children/adolescents currently receiving AAP mono-
therapy. The most common were aggression (24%), anxiety (18%)
and conduct disorder (16%). Almost half (45%) of children/adoles-
cents receiving AAP monotherapy were reported to have no co-
morbid conditions/behaviours. The highest rates of AAP mono-
therapy for children/adolescents with no comorbidities were re-
ported in ‘Nordic countries’ (88%), Sweden (80%) and Spain (61%).
For each country, broadly similar rates of use of ADHD medi-
cation classes were reported among children/adolescents who
were currently on or off medication; Table 4).
Table 3
Behavioural therapya for children/adolescents with ADHD as reported by caregivers.
Children/adolescents with
ADHD
Pan-EU
(N¼3688)
France
(n¼486)
Germany
(n¼589)
Italy
(n¼468)
Netherlands
(n¼316)
Nordicsb
(n¼249)
Sweden
(n¼219)
Spain
(n¼574)
UK
(n¼787)
Behavioural therapy experience
Ever received since
diagnosis
2047 (55.5) 287 (59.1) 370 (62.8) 360 (76.9) 151 (47.8) 98 (39.4) 50 (22.8) 375 (65.3) 356 (45.2)
Received prior to
medication
1327 (36.0) 149 (30.7) 246 (41.8) 284 (60.7) 80 (25.3) 62 (24.9) 24 (11.0) 258 (44.9) 224 (28.5)
Presently receiving 1073 (29.1) 194 (39.9) 164 (27.8) 247 (52.8) 40 (12.7) 48 (19.3) 23 (10.5) 201 (35.0) 156 (19.8)
Duration of behavioural
therapy before starting
medication
(n¼1327) (n¼149) (n¼246) (n¼284) (n¼80) (n¼62) (n¼24) (n¼258) (n¼224)
o1 month 142 (10.7) 13 (8.7) 19 (7.7) 33 (11.6) 5 (6.3) 5 (8.1) 8 (33.3) 35 (13.6) 24 (10.7)
1 month to o6 months 609 (45.9) 53 (35.6) 103 (41.9) 134 (47.2) 39 (48.8) 30 (48.4) 13 (54.2) 111 (43.0) 126 (56.3)
6 months to o12 months 345 (26.0) 45 (30.2) 72 (29.3) 92 (32.4) 22 (27.5) 15 (24.2) 3 (12.5) 51 (19.8) 45 (20.1)
1 year to o2 years 132 (9.9) 19 (12.8) 32 (13.0) 15 (5.3) 5 (6.3) 5 (8.1) 0 (0.0) 36 (14.0) 20 (8.9)
Z2 years 99 (7.5) 19 (12.8) 20 (8.1) 10 (3.5) 9 (11.3) 7 (11.3) 0 (0.0) 25 (9.7) 9 (4.0)
Reasons for ending beha-
vioural therapyc
(n¼974) (n¼93) (n¼206) (n¼113) (n¼111) (n¼50) (n¼27) (n¼174) (n¼200)
Did not improve
hyperactivity
185 (19.0) 16 (17.2) 42 (20.4) 14 (12.4) 16 (14.4) 9 (18.0) 6 (22.2) 39 (22.4) 43 (21.5)
Did not improve
impulsivity
164 (16.8) 21 (22.6) 34 (16.5) 17 (15.0) 14 (12.6) 5 (10.0) 4 (14.8) 29 (16.7) 40 (20.0)
Did not improve
concentration
247 (25.4) 32 (34.4) 58 (28.2) 17 (15.0) 22 (19.8) 10 (20.0) 7 (25.9) 51 (29.3) 50 (25.0)
Did not improve behaviour 207 (21.3) 23 (24.7) 48 (23.3) 15 (13.3) 20 (18.0) 8 (16.0) 4 (14.8) 35 (20.1) 54 (27.0)
(At least one of the above) 432 (44.4) 57 (61.3) 87 (42.2) 46 (40.7) 34 (30.6) 16 (32.0) 11 (40.7) 82 (47.1) 99 (49.5)
No longer needed with
medication
295 (30.3) 20 (21.5) 53 (25.7) 41 (36.3) 39 (35.1) 17 (34.0) 4 (14.8) 68 (39.1) 53 (26.5)
Child did not want therapy 168 (17.2) 24 (25.8) 33 (16.0) 22 (19.5) 19 (17.1) 11 (22.0) 10 (37.0) 14 (8.0) 35 (17.5)
No additional sessions
available
155 (15.9) 13 (14.0) 51 (24.8) 13 (11.5) 15 (13.5) 10 (20.0) 3 (11.1) 16 (9.2) 34 (17.0)
Otherd 113 (11.6) 7 (7.5) 21 (10.2) 4 (3.5) 33 (29.7) 11 (22.0) 8 (29.6) 26 (14.9) 10 (5.0)
All numbers are reported as n (%) unless stated otherwise.
ADHD, attention-deﬁcit/hyperactivity disorder.
a Refers speciﬁcally to therapy for the child/adolescent, and also includes cognitive behavioural therapy. It is considered unlikely that caregivers included psycho-
education within the category of behavioural therapy.
b Denmark, Finland and Norway.
c More than one reason could be selected by each participant.
d Includes ‘problems solved/not helpful’, ‘dissatisﬁed’, ‘doctor recommendation’, ‘unavailable’.
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A greater proportion of caregivers reported that their child had
no difﬁculty with social interactions (20% vs 9%; po0.0001 dis-
tribution of responses on vs off ADHD medication; Table 5). A
greater proportion of caregivers also reported that their child had
no difﬁculty with schoolwork (12% vs 2%) and there was no strain
on the child's relationships with their caregiver (19% vs 7%) or
siblings (17% vs 7%), when on medication compared with off
medication (Table 5). However, a large proportion (80–88%) still
reported some level of difﬁculty or strain in these domains when
their child/adolescent was on medication (Table 5).
More caregivers reported no difﬁculty in their own social ac-
tivities (32% vs 21%) and no strain in their relationship with their
partner (24% vs 12%) and other children (31% vs 18%) when their
child was on medication compared with off medication (Table 5).
However, 68–76% still reported some level of difﬁculty/strain in
these domains even when on medication (Table 5).
Signiﬁcantly greater proportions of caregivers did not avoid
taking their child to outside activities (39% vs 29%), did not avoid
social activities (39% vs 28%) or got less enjoyment from them (34%
vs 23%), and did not worry about other's perceptions of them as a
parent (34% vs 28%) when their child/adolescent was on versus off
ADHD medication (Table 5; po0.0001 distribution of responses
for each of the domains). As before, however, 61–66% still reportedsome levels of difﬁculty or strain in these domains even when
their child/adolescent was on medication.
More than a third (38%) of caregivers reported being late for
work due to their child's ADHD in the past 4 weeks, with a mean
(SD) 3.8 (8.1) hours of work being missed during this time
(Table 6). Almost a third (31%) of caregivers reported having to
alter their employment status due to their child/adolescent's
ADHD; more than half (53%) of these changes occurred when the
child/adolescent was on medication.4. Discussion
Here we have described the sociodemographic and clinical
characteristics of caregivers and children/adolescents with ADHD,
and treatment use, reported in the CAPPA survey for 10 individual
countries and the overall sample. We have also reported ﬁndings
on the inﬂuence of medication on the burden on work, school and
relationships that is associated with ADHD.
Caregiver-reported data from this survey provide useful in-
formation about diagnosis and severity of ADHD among children/
adolescents across Europe and the prevalence of comorbid con-
ditions/behaviours. In our survey, children/adolescents were re-
ported to be diagnosed with ADHD at the youngest age in France
(6.3 years) and oldest in Sweden (8.3 years). The overall reported
Table 4
Categories of medicationsa either currently or most recentlyb received by children/adolescents reported by caregivers.
Pan-EU
(N¼3688)
France
(n¼486)
Germany
(n¼589)
Italy
(n¼468)
Netherlands
(n¼316)
Nordics
(n¼249) c
Sweden
(n¼219)
Spain
(n¼574)
UK
(n¼787)
Current Most
recent
Current Most
recent
Current Most
recent
Current Most
recent
Current Most
recent
Current Most
recent
Current Most
recent
Current Most
recent
Current Most
recent
Children/adoles-
cents with
ADHD
2890 (78.4) 798 (21.6) 374 (77.0) 112 (23.0) 465 (79.0) 124 (21.1) 316 (67.5) 152 (32.5) 272 (86.1) 44 (13.9) 202 (81.1) 47 (18.9) 176 (80.4) 43 (19.6) 453 (78.9) 121 (21.1) 632 (80.3) 155 (19.7)
Any use
Stimulant 2394 (82.8) 612 (76.7) 276 (73.8) 89 (79.5) 434 (93.3) 112 (90.3) 189 (59.8) 81 (53.3) 254 (93.4) 38 (86.4) 177 (87.6) 40 (85.1) 152 (86.4) 36 (83.7) 378 (83.4) 91 (75.2) 534 (84.5) 125 (80.6)
Non-stimulant 239 (8.3) 53 (6.6) 57 (15.2) 5 (4.5) 23 (4.9) 4 (3.2) 20 (6.3) 8 (5.3) 3 (1.1) 1 (2.3) 27 (13.4) 7 (14.9) 32 (18.2) 10 (23.3) 30 (6.6) 11 (9.1) 47 (7.4) 7 (4.5)
Antipsychotic 468 (16.2) 169 (21.2) 81 (21.7) 26 (23.2) 29 (6.2) 9 (7.3) 146 (46.2) 63 (41.4) 19 (7.0) 4 (9.1) 25 (12.4) 6 (12.8) 13 (7.4) 4 (9.3) 85 (18.8) 33 (27.3) 70 (11.1) 24 (15.5)
Other 163 (5.6) 48 (6.0) 17 (4.5) 10 (8.9) 7 (1.5) 3 (2.4) 5 (1.6) 8 (5.3) 17 (6.3) 3 (6.8) 21 (10.4) 3 (6.4) 18 (10.2) 2 (4.7) 12 (2.6) 2 (1.7) 66 (10.4) 17 (11.0)
Monotherapy
Stimulant 2175 (75.3) 546 (68.4) 239 (63.9) 77 (68.8) 410 (88.2) 107 (86.3) 152 (48.1) 68 (44.7) 245 (90.1) 37 (84.1) 155 (76.7) 32 (68.1) 131 (74.4) 28 (65.1) 341 (75.3) 78 (64.5) 502 (79.4) 119 (76.8)
Non-stimulant 162 (5.6) 26 (3.3) 48 (12.8) 2 (1.8) 12 (2.6) 2 (1.6) 10 (3.2) 5 (3.3) 3 (1.1) 1 (2.3) 14 (6.9) 2 (4.3) 17 (9.7) 4 (9.3) 21 (4.6) 4 (3.3) 37 (5.9) 6 (3.9)
Antipsychotic 284 (9.8) 121 (15.2) 43 (11.5) 15 (13.4) 15 (3.2) 6 (4.8) 108 (34.2) 53 (34.9) 10 (3.7) 3 (6.8) 8 (4.0) 3 (6.4) 5 (2.8) 1 (2.3) 51 (11.3) 23 (19.0) 44 (7.0) 17 (11.0)
Other 37 (1.3) 35 (4.4) 4 (1.1) 5 (4.5) 4 (0.9) 4 (3.2) 5 (1.6) 13 (8.6) 5 (1.8) 2 (4.5) 0 (0.0) 2 (4.3) 2 (1.1) 2 (4.7) 2 (0.4) 1 (0.8) 15 (2.4) 6 (3.9)
Combination therapy
Antipsychotic
and stimulant
155 (5.4) 43 (5.4) 31 (8.3) 10 (8.9) 13 (2.8) 3 (2.4) 31 (9.8) 10 (6.6) 9 (3.3) 1 (2.3) 12 (5.9) 3 (6.4) 6 (3.4) 2 (4.7) 29 (6.4) 8 (6.6) 24 (3.8) 6 (3.9)
Antipsychotic
and non-
stimulant
13 (0.4) 4 (0.5) 3 (0.8) 1 (0.9) 0 (0.0) 0 (0.0) 4 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) 2 (1.7) 2 (0.3) 1 (0.6)
Stimulant and
non-stimulant
48 (1.7) 22 (2.8) 2 (0.5) 2 (1.8) 10 (2.2) 2 (1.6) 3 (0.9) 3 (2.0) 0 (0.0) 0 (0.0) 8 (4.0) 5 (10.6) 13 (7.4) 5 (11.6) 4 (0.9) 5 (4.1) 8 (1.3) 0 (0.0)
Antipsychotic,
stimulant and
non-stimulant
16 (0.6) 1 (0.1) 4 (1.1) 0 (0.0) 1 (0.2) 0 (0.0) 3 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0) 0 (0.0) 2 (1.1) 1 (2.3) 4 (0.9) 0 (0.0) 0 (0.0) 0 (0.0)
All numbers are reported as n (%) unless stated otherwise.
ADHD, attention-deﬁcit/hyperactivity disorder.
a A predeﬁned list of medications including those indicated for ADHD as well as atypical antipsychotics that are not indicated for ADHD but are used widely (Sikirica et al., 2013b) was provided for the caregiver to select from;
an ‘Other’ ﬁeld was also included to allow free text responses.
b Applies only to children/adolescents who were not currently receiving pharmacotherapy; reﬂects pharmacotherapy use within the last 6 months.
c Denmark, Finland and Norway.
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Table 5
Difﬁculties, strains and time-related impacts described by caregivers of children with ADHD on versus off medication.
Characteristic: difﬁculties A tremendous amount A lot A moderate amount A little No difﬁculty
How much difﬁculty does your child have with schoolwork due
to ADHD? (n¼3153)
On medication 122 (3.9) 505 (16.0) 985 (31.2) 1178 (37.4) 363 (11.5)
Off medication 1101 (34.9) 1054 (33.4) 722 (22.9) 214 (6.8) 62 (2.0)
How much difﬁculty has your child had with social interactions with peers due to ADHD?n (n¼3153)
On medication 149 (4.7) 405 (12.8) 852 (27.0) 1110 (35.2) 637 (20.2)
Off medication 750 (23.8) 858 (27.2) 790 (25.1) 465 (14.7) 290 (9.2)
How much difﬁculty did you have participating in social activities? (n¼3153)
On medication 161 (5.1) 325 (10.3) 656 (20.8) 997 (31.6) 1014 (32.2)
Off medication 598 (19.0) 632 (20.0) 689 (21.9) 581 (18.4) 653 (20.7)
Characteristic: strain A tremendous amount A lot A moderate amount A little No strain
How much strain did your child's ADHD put on relationship with you? (n¼3153)
On medication 123 (3.9) 351 (11.1) 889 (28.2) 1202 (38.1) 588 (18.6)
Off medication 784 (24.9) 920 (29.2) 783 (24.8) 447 (14.2) 219 (6.9)
How much strain did your child's ADHD put on their relationship with siblings? (n¼2725)
On medication 133 (4.9) 355 (13.0) 757 (27.8) 1024 (37.6) 456 (16.7)
Off medication 748 (27.4) 782 (28.7) 626 (23.0) 366 (13.4) 203 (7.4)
How much strain did your child's ADHD put on your relationship with your partner? (n¼2843)
On medication 127 (4.5) 343 (12.1) 697 (24.5) 997 (35.1) 679 (23.9)
Off medication 583 (20.5) 676 (23.8) 723 (25.4) 515 (18.1) 346 (12.2)
How much strain did your child's ADHD put on your relationship with your other children? (n¼2725)
On medication 79 (2.9) 227 (8.3) 592 (21.7) 986 (36.2) 841 (30.9)
Off medication 364 (13.4) 623 (22.9) 697 (25.6) 553 (20.3) 488 (17.9)
Characteristic: time A tremendous amount A lot A moderate amount A little No time
How much time did you spend worrying or stressing about your child? (n¼3153)
On medication 352 (11.2) 602 (19.1) 861 (27.3) 1006 (31.9) 332 (10.5)
Off medication 925 (29.3) 915 (29.0) 720 (22.8) 456 (14.5) 137 (4.3)
Characteristic: how often over the past 6 months did you
do each of the following:
Almost all the time
(490%)
Most of the
time (75%)
Some of the time
(50%)
A little of the
time (25%)
Never (0%)
Keep in close contact with school/teachersn (n¼3153)
On medication 576 (18.3) 493 (15.6) 745 (23.6) 1033 (32.8) 306 (9.7)
Off medication 990 (31.4) 700 (22.2) 747 (23.7) 534 (16.9) 182 (5.8)
Avoid taking child to activities outside of homen (n¼3153)
On medication 176 (5.6) 274 (8.7) 591 (18.7) 879 (27.9) 1233 (39.1)
Off medication 538 (17.1) 494 (15.7) 659 (20.9) 541 (17.2) 921 (29.2)
Avoid social activities when with the childn (n¼3153)
On medication 174 (5.5) 279 (8.8) 547 (17.3) 936 (29.7) 1217 (38.6)
Off medication 577 (18.3) 478 (15.2) 662 (21.0) 544 (17.3) 892 (28.3)
Get less enjoyment from social activities when with the childn
(n¼3153)
On medication 210 (6.7) 288 (9.1) 603 (19.1) 975 (30.9) 1077 (34.2)
Off medication 597 (18.9) 563 (17.9) 657 (20.8) 619 (19.6) 717 (22.7)
Worry of other’s perceptions of me as a parentn (n¼3153)
On medication 344 (10.9) 313 (9.9) 547 (17.3) 865 (27.4) 1084 (34.4)
Off medication 722 (22.9) 466 (14.8) 540 (17.1) 538 (17.1) 887 (28.1)
All data are given as n (%). Responses relate to the 6-month period prior to the survey.
n po0.0001; Wilcoxon Signed Rank test comparing the distribution of responses on versus off medication.
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Table 6
Impact of child/adolescent's ADHD on the caregiver's work.
Characteristic Overall
(N¼3688)
In the past 4 weeks, how many hours of work did you miss dealing with your
child’s ADHD?a
n 2872
Mean (SD) 3.8 (8.1)
Median 1
Q1–Q3 0–5
Range 0–148
In the past 4 weeks, were you ever late for work due to your child’s ADHD?
n 2875
Yes 1097 (38.2)
No 1778 (61.8)
In the past 4 weeks, how many times were you late for work due to your child’s
ADHD?
n 1097
Mean (SD) 3.47 (3.16)
Median 2
Q1–Q3 2–4
Range 1–25
Have you had to alter your employment due to your child’s ADHD?
n 3688
Yes, had to change job 145 (3.9)
Yes, had to change work shift 300 (8.1)
Yes, had to cut back hours 505 (13.7)
Yes, had to quit working 210 (5.7)
No 2528 (68.5)
Did the work change happen while your child was on ADHD medications?
n 1160
Yes 617 (53.2)
No 543 (46.8)
All data given as n (%) unless speciﬁed otherwise
a Three outliers who reported 4160 work hours missed in 4 weeks were
excluded from this analysis.
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practice guideline recommendations (American Academy of Pe-
diatrics, 2011; NICE, 2013; Taylor et al., 2004). It is widely re-
cognized that ADHD should be diagnosed as early as possible
(European Commission ADHD Project, 2002); a valid diagnosis can
be made in children aged 5–6 years but the diagnosis of younger
children is challenging (Taylor et al., 2004). The mean age at di-
agnosis in our survey is also in line with estimates of 6.6–10.0
years in previous observational studies of ADHD in Europe
(Hodgkins et al., 2013; Preuss et al., 2006; Raman et al., 2015).
Reported severity of ADHD (while receiving treatment) varied
among countries. For example, 12% of caregivers in Italy reported
that their child/adolescent's ADHD was severe/very severe com-
pared with 33% in Germany and the Netherlands. This variation
may be attributable to country- and/or centre-speciﬁc differences
in ADHD treatment practice. Cultural attitudes affect perceptions
of child behaviour and social factors inﬂuence the degree of child
behaviour that is considered problematic (Singh, 2008). For ex-
ample, families, schools and wider cultures vary in their tolerance
of hyperactivity (Ho et al., 1996). Such cultural differences in how
caregivers perceive and interpret ADHD-related symptoms/beha-
viours could contribute to the variation observed across Europe in
our survey.
According to caregivers’ reports, almost half (49%) of children/
adolescents with ADHD had at least one current physician-diag-
nosed comorbid condition/behaviour, most frequently anxiety,learning difﬁculties, conduct disorder or aggression. This general
prevalence of comorbidities is consistent with rates reported by
physicians in a previous observational study in Germany (Weh-
meier et al., 2015) and a retrospective pan-European chart review
(Hodgkins et al., 2013) but lower than in a Danish naturalistic
study (Powell et al., 2011). Notably, the rates of most common
comorbid psychiatric conditions reported by caregivers in the
CAPPA population are lower than in the physician-reported
Attention Deﬁcit/Hyperactivity Disorder Observational Research in
Europe (ADORE) study (Steinhausen et al., 2006).
The lower than expected rate of comorbidities in the CAPPA
survey might be related to under-reporting by caregivers. In this
survey, data on comorbidities are based on caregiver rather than
physician reporting. Caregivers may be poorly informed of co-
morbidities and so may not recognize particular conditions/
behaviours. In addition, the likelihood of caregiver reporting may
be inﬂuenced by the relative impact of comorbidities on daily life.
Moreover, caregivers may not perceive that the comorbid condi-
tion/behaviour still exists if their child/adolescent has received
appropriate treatment.
Treatment use data should be evaluated in the context of Eur-
opean ADHD management guidelines (Deutsche Gesellschaft für
Kinder- und Jugendpsychiatrie und Psychotherapie, 2007; Health
Ministry of Spain, 2010; Landelijke Stuurgroep, 2007; NICE, 2013;
Seixas et al., 2012; SINPIA, 2002; Taylor et al., 2004). Current
guidelines recommend that non-pharmacological treatment
should be initiated before prescription medications in all but se-
vere cases of ADHD. However, recent meta-analyses have shown
limited efﬁcacy of non-pharmacological interventions in ADHD,
suggesting that treatment guidelines should perhaps be revisited
(Cortese et al., 2015; Daley et al., 2014; Rapport et al., 2013; So-
nuga-Barke et al., 2013). In our survey, the highest rates of BT use
were reported in Italy, Germany and Spain, and possibly reﬂect
good adherence to current ADHD treatment recommendations in
these countries. Overall, 23–77% of children/adolescents were re-
ported to have not received BT. This ﬁnding is consistent with a
recent retrospective medical record review in which children/
adolescents with ADHD were followed for at least 2 years after
diagnosis in six European countries (Setyawan et al., 2015). Only
15% of children/adolescents in the Italian sample received no BT,
whereas BT was not used in at least half of cases (50–53%) in the
Netherlands, France and the UK (Setyawan et al., 2015).
All children/adolescents included in this survey were currently
receiving medication for ADHD or had done so in the previous
6 months. During the survey, caregivers were asked to select re-
levant ADHD medications from a predeﬁned list that included
AAPs. Although AAPs are not licensed for the treatment of ADHD,
they are prescribed for a substantial proportion of children/ado-
lescents with ADHD worldwide (Ben Amor et al., 2014; Betts et al.,
2014; Sikirica et al., 2012, 2013b; Wong et al., 2014). Indeed, the
most common treatment combination currently being received by
children/adolescents in this study was a stimulant plus an AAP
(5.4%). It is possible that the AAP use reported in this survey was
prescribed to treat comorbid conditions rather than ADHD per se.
However, given the low rates of reported comorbidities in this
study, the widespread use of AAPs among children/adolescents
with ADHD warrants further investigation.
In most countries, the pattern of use of medications was similar
among children/adolescents who recently received pharma-
cotherapy and those currently receiving pharmacotherapy. How-
ever, in France, the use of non-stimulant medications was more
common among current than recent medication users. This ﬁnding
was unexpected as the non-stimulant atomoxetine is not available
in France (unlike in other European countries). Further investiga-
tion is needed to ascertain if this could be explained by cross-
border or ‘exceptional’ prescribing of atomoxetine by French
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ADHD had a considerable impact on the lives of children/ado-
lescents in this study. Almost a quarter of children/adolescents
with ADHD in this survey had repeated a school year; the lowest
rates of grade repetition were reported in the UK and Italy. Edu-
cational culture, regulations and legislation governing grade re-
petition vary greatly among European countries (Eurydice, 2011).
In the UK, children/adolescents repeat a school year only in ex-
ceptional circumstances (Eurydice, 2011). Population-wide esti-
mates from 2009 suggest that 2% of pupils aged 15 years have
repeated a school year in the UK versus 16% in Italy, 35% in Spain
and 37% in France (OECD, 2010). Cultural differences towards
grade repetition across European countries undoubtedly con-
tribute to the widely different rates among patients with ADHD
reported in this survey. For example, in some countries including
Spain, France and the Netherlands, a common belief held by both
teaching staff and parents is that repeating a year is beneﬁcial for
pupils’ learning (Eurydice, 2011).
Overall, 15% of children/adolescents with ADHD in this survey
attended a special needs school; the lowest rate (5%) was reported
in Spain. Notably, at the time of this survey, ADHD was not re-
cognized as a condition that requires special educational needs
under Spanish law. However, a recently approved educational law
does include ADHD and, therefore, we expect that the proportion
of children/adolescents with ADHD who attend special needs
schools in Spain will increase in the future (No authors listed,
2015). It should be noted that the survey did not assess the reasons
for attending special needs schools, and the relationship between
speciﬁc comorbidities and special needs school attendance was
not investigated.
In the current survey, 4% of children/adolescents were reported
by their caregivers to have been permanently expelled from school
within the last 6 months. There are minimal published standar-
dized data on school expulsion rates among children with or
without ADHD across Europe. However, published data suggest
that 0.06% of pupils (or 0.15–0.23% of those with special educa-
tional needs) were expelled from state-funded schools in England
during the 2012–13 academic year (UK Department for Education,
2014). In the CAPPA study, 5.3% of children/adolescents (with
ADHD) in the UK were reported by caregivers to have been ex-
pelled in the last 6 months; this is substantially higher than the
published expulsion rate in England. The survey did not provide an
explicit deﬁnition to distinguish between the terms ‘exclusion’ and
‘expulsion’. Thus, it is possible that caregivers in our survey may
have not consistently differentiated between temporary exclusion
and permanent expulsion in their responses, which may have re-
sulted in the incidence of expulsion being over-reported.
In the ADORE study, 73% of parents reported that their child/
adolescent with ADHD caused conﬂict or tension within the family
at least sometimes, and 73% also reported limited time to relax or
participate in social activities (Riley et al., 2006b). Our ﬁndings are
generally in line with these data. In the CAPPA survey, more
caregivers reported that their child/adolescent had no difﬁculty
with schoolwork or social interactions and caused no strain on
family relationships when on versus off medication, but the vast
majority (80–88%) reported some degree of difﬁculty or strain in
these domains even when the child was receiving medication.
Similarly, the majority of caregivers (68–76%) reported some level
of difﬁculty or strain in their own social activities and family re-
lationships even when their child was on medication.
Almost a third of caregivers altered their employment status
(e.g. reduced their working hours or resigned) because of their
child/adolescent's ADHD. These changes were required despite the
child/adolescent being on medication in more than half of cases
(53%), suggesting that there may still be unmet needs in the
management of ADHD. Our ﬁndings are broadly in line withprevious research showing the negative effect of ADHD on chil-
dren/adolescents and their families, although differing study de-
signs prevent direct comparison of data (Caci et al., 2014; Coghill
et al., 2008; Kvist et al., 2013; Le et al., 2013; Noe and Hankin,
2001).
A number of potential limitations of this study should be noted.
The CAPPA study was conducted from the caregiver's perspective
and so may be subject to reporting and/or recall biases. The re-
ported information may be inﬂuenced by caregivers’ under-
standing of ADHD, their cultural beliefs and other underlying
characteristics. As such, the survey ﬁndings should not be ex-
pected to be fully consistent with formal clinical assessments.
Furthermore, there are likely to be differences in the way clinical
information is conveyed to caregivers across Europe. This would
make direct comparisons of caregiver reported data on the impact
of ADHD between different countries challenging. In addition, the
survey was based on an assumption that the caregivers had rea-
sonable recall of their child/adolescent's ADHD when on versus off
medication. Some children/adolescents were still receiving ADHD
medication whereas others had discontinued up to 6 months
previously. This variable recall period could lead to bias in care-
giver responses.
Participants were recruited as a convenience sample through
patient panels, which could introduce selection bias. For example,
unemployment rates reported by caregivers in this survey in most
countries were substantially lower than population-wide data
from the same time period reported elsewhere (Eurostat, 2015). In
addition, a large proportion of caregivers in the CAPPA survey
were married (81%), which does not seem consistent with the high
risk of divorce reported for parents of children/adolescents with
ADHD and could indicate a selection bias (Kvist et al., 2013;
Schermerhorn et al., 2012; Wymbs et al., 2008). One could spec-
ulate that divorced or single parents may have little time to par-
ticipate in such surveys and, thus, the sample may have been
biased towards married caregivers. Furthermore, the reported rate
of ADHD among parental caregivers in this study was low (8%).
High heritability (around 76%) of ADHD has been reported in twin
studies of children and adolescents (Faraone et al., 2005) and, in a
US study, childhood ADHD was shown to be more prevalent
among mothers of children with ADHD than mothers of children
without ADHD (Chronis et al., 2003). The low reported rate of
ADHD among parents in our study may reﬂect a bias towards
participation by caregivers without ADHD, or more general under-
diagnosis and treatment of ADHD among adults in Europe (Gins-
berg et al., 2014; Ramos-Quiroga et al., 2013).
Within-country heterogeneity may also be a study limitation as
the geographic representativeness of samples within each country
was not evaluated. In particular, families from villages or rural
areas with lower socio-economic status may be under-represented
because of the need for internet access to take part in this web-
based survey.
In conclusion, this large cross-sectional survey provides valu-
able real-world observations from caregivers in 10 European
countries on children/adolescents with ADHD who were currently
receiving or had recently received pharmacotherapy. Descriptive
data indicate that there is wide variation across Europe in the
sociodemographic and clinical characteristics of caregivers and
children/adolescents with ADHD, and in treatment use. There is
also variation between countries in rates of reported ADHD co-
morbid conditions/behaviours. BT was a widely used treatment
modality in some countries but rates varied across Europe; 29% of
children/adolescents were reported to be currently receiving BT.
Most children/adolescents (78%) were currently receiving phar-
macological treatment; the majority received stimulants but high
rates of AAP use were reported in some countries. Although ADHD
medication helped to improve symptoms, the disorder was still
E. Flood et al. / Journal of Affective Disorders 200 (2016) 222–234 233associated with a considerable burden on the lives of caregivers
and their child/adolescent. A negative effect of ADHD was seen on
the caregiver's work and child's schoolwork, and on their re-
lationships with family and friends. Indeed, most caregivers re-
ported that their child/adolescent had difﬁculty with schoolwork
due to ADHD and 4% had been expelled from school in the last
6 months; these data underscore the impact of ADHD on academic
functioning. Our ﬁndings also highlight the need to further im-
prove functional outcomes even among children/adolescents who
are receiving medication for ADHD.Role of funding source
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